These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 36320966)

  • 21. Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies.
    Chen J; Song S; Li X; Bian D; Wu X
    Saudi J Gastroenterol; 2022; 28(2):92-100. PubMed ID: 34810377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives.
    Ueno M; Takeda H; Takai A; Seno H
    World J Gastroenterol; 2022 Jul; 28(27):3410-3421. PubMed ID: 36158261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease: Potential mechanistic pathways.
    Perumpail RB; Liu A; Wong RJ; Ahmed A; Harrison SA
    World J Hepatol; 2015 Oct; 7(22):2384-8. PubMed ID: 26464753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
    Zhang X; Coker OO; Chu ES; Fu K; Lau HCH; Wang YX; Chan AWH; Wei H; Yang X; Sung JJY; Yu J
    Gut; 2021 Apr; 70(4):761-774. PubMed ID: 32694178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
    Farrell GC; Larter CZ
    Hepatology; 2006 Feb; 43(2 Suppl 1):S99-S112. PubMed ID: 16447287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship.
    Muzica CM; Sfarti C; Trifan A; Zenovia S; Cuciureanu T; Nastasa R; Huiban L; Cojocariu C; Singeap AM; Girleanu I; Chiriac S; Stanciu C
    Can J Gastroenterol Hepatol; 2020; 2020():6638306. PubMed ID: 33425804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.
    Makri E; Goulas A; Polyzos SA
    Arch Med Res; 2021 Jan; 52(1):25-37. PubMed ID: 33334622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonalcoholic fatty liver disease in children and adolescents - Relationship with Polycystic Ovary Syndrome.
    Abruzzese GA; Motta AB
    Curr Pharm Des; 2015; 21(35):5144-50. PubMed ID: 26412465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonalcoholic fatty liver disease and polycystic ovary syndrome.
    Vassilatou E
    World J Gastroenterol; 2014 Jul; 20(26):8351-63. PubMed ID: 25024594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease.
    Ferolla SM; Armiliato GN; Couto CA; Ferrari TC
    World J Hepatol; 2015 Mar; 7(3):559-65. PubMed ID: 25848479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.
    Song Q; Zhang X
    Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease.
    Eslamparast T; Eghtesad S; Poustchi H; Hekmatdoost A
    World J Hepatol; 2015 Feb; 7(2):204-12. PubMed ID: 25729475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies.
    Vetrano E; Rinaldi L; Mormone A; Giorgione C; Galiero R; Caturano A; Nevola R; Marfella R; Sasso FC
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Current View of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma.
    Kogiso T; Tokushige K
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33572797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review.
    Tariq R; Axley P; Singal AK
    J Clin Exp Hepatol; 2020; 10(1):81-87. PubMed ID: 32025167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
    Miura K; Ohnishi H
    World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathogenesis and management issues for non-alcoholic fatty liver disease.
    Duvnjak M; Lerotić I; Barsić N; Tomasić V; Virović Jukić L; Velagić V
    World J Gastroenterol; 2007 Sep; 13(34):4539-50. PubMed ID: 17729403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease.
    Chen G; Ni Y; Nagata N; Xu L; Ota T
    Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27563875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.